Open AccessNew‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report
Author(s) -
Kobayashi Takaaki,
Yakou Fumiyoshi,
Saburi Masuo,
Hirose Ai,
Akaoka Hiroaki,
Hirota Yusuke,
Yunaiyama Daisuke,
Asahi Nobuteru,
Ohno Atsushi,
Matsushita Takaya
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.6473
Subject(s) - medicine , fulminant , vaccination , type 1 diabetes , covid-19 , diabetes mellitus , antibody , immunology , disease , glutamate decarboxylase , pediatrics , infectious disease (medical specialty) , endocrinology , biochemistry , chemistry , enzyme
Adverse reactions, including the onset of diabetes, after coronavirus disease 2019 (COVID‐19) vaccination have been reported. Herein, we report a case of a man who developed anti‐glutamic acid decarboxylase (GAD) antibody‐positive fulminant type 1 diabetes 15 weeks after COVID‐19 vaccination, atypical of the previously reported anti‐GAD antibody‐negative cases.